Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT07059611 · ClinicalTrials.gov registry record · Phase 2
Neoadjuvant Intra-tumoral RP2 and FLOT in Gastroesophageal Adenocarcinoma
A Phase 2 study, sponsored by Abramson Cancer Center at Penn Medicine.
- Not yet
- Registry status
- Phase 2
- Development phase
- 34
- Enrollment target
NCT07059611: Clinical Trial Phase 2 study, sponsored by Abramson Cancer Center at Penn Medicine.
NCT07059611 is a Phase 2 study that has not yet begun recruiting, run by Abramson Cancer Center at Penn Medicine. The registered enrollment target is 34 participants, below the 133-participant average among 30,622 other Phase 2 trials with a reported enrollment target (74% lower). According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT07059611, a Phase 2 study, has not yet begun recruiting, sponsored by Abramson Cancer Center at Penn Medicine.
- NOT YET RECRUITING
- Registry status
- Phase 2
- Development phase
- 34 participants
- Enrollment target
Study Summary
The research study is being conducted to study whether performing injections of a new treatment, called RP2, directly into stomach and esophagus tumors along with standard chemotherapy (called FLOT) is safe and whether it does a better job of killing cancer before surgery compared to chemotherapy alone.
Primary Outcome
Pathologic complete response defined as the absence of residual invasive cancer on histologic examination of the resected esophageal, GEJ, or gastric adenocarcinoma specimen and all sampled regional lymph nodes. This will be assessed in the efficacy population who received at least three intra-tumoral injections of RP2 and underwent subsequent surgical resection.
Interventions
- BIOLOGICAL RP2
- COMBINATION_PRODUCT 5-Fluorouracil
- COMBINATION_PRODUCT Leucovorin
- COMBINATION_PRODUCT Oxaliplatin
- COMBINATION_PRODUCT Docetaxel
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 34 participants |
| Start Date | 2026-09-01 |
| Est. Completion | 2029-11-01 |
| Phase | Phase 2 |
What is known before NCT07059611 opens enrollment
NCT07059611 is an interventional study that assigns participants to a tested intervention. The registry caps enrollment at 34 participants, a relatively small participant target, below the 133-participant average among 30,622 other Phase 2 trials with a reported enrollment target (74% lower).
The record links to 0 conditions, and to 5 interventions - of which RP2 is the first listed.
NCT07059611 does not publish any study locations in the registry export this page uses.
Frequently Asked Questions
What is clinical trial NCT07059611 about?
NCT07059611 is a clinical study titled "Neoadjuvant Intra-tumoral RP2 and FLOT in Gastroesophageal Adenocarcinoma". The research study is being conducted to study whether performing injections of a new treatment, called RP2, directly into stomach and esophagus tumors along with standard chemotherapy (called FLOT) is safe and whether it does a better job of killing cancer before surgery compared to chemotherapy al...
What is the current status of trial NCT07059611?
This trial is currently not yet recruiting. It is a Phase 2 study. The enrollment target is 34 participants. The study started on 2026-09-01. Estimated completion is 2029-11-01.
What interventions are being tested in trial NCT07059611?
The interventions under investigation include: RP2 (BIOLOGICAL), 5-Fluorouracil (COMBINATION_PRODUCT), Leucovorin (COMBINATION_PRODUCT), Oxaliplatin (COMBINATION_PRODUCT), Docetaxel (COMBINATION_PRODUCT).
Who is sponsoring clinical trial NCT07059611?
This trial is sponsored by Abramson Cancer Center at Penn Medicine, which has 402 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
How this trial's enrollment target compares
Where NCT07059611's enrollment target sits among peer trials
34 1539th of 2000 higher than 448 of 2,000 other Phase 2 trials
participants (enrollment target), bucketed by value
Each bar is a band; taller bars hold more other Phase 2 trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.
Source ClinicalTrials.gov registry export · 2026-08-08
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT02897063 · 34 participants · Phase 1
Effects of Midodrine and Droxidopa on Splanchnic Capacitance in Autonomic Failure
- NCT03906617 · 34 participants · Phase 4
Bupivacaine/Epinephrine +Dexamethasone vs. Liposomal Bupivacaine
- NCT03992378 · 34 participants · NA
Neuromodulation to Regulate Inflammation and Autonomic Imbalance in Sepsis
- NCT04047849 · 34 participants · Phase 4
Latency Antibiotics in Previable PPROM, 18 0/7- 22 6/7 WGA
Similar registry start date
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia
- NCT07125183 · started 2026-12 · Phase 2
Study on Efficacy and Tolerability of Weekly Doxorubicin in Elderly Patients With Advanced or Metastatic Leiomyosarcoma
- NCT07292298 · started 2026-11 · Phase 2
Phase 2 Single-Arm Rectal Cancer Brachytherapy for Patients With Low-Lying Residual Adenocarcinoma After Total Neoadjuvant Therapy to Improve Organ Preservation Rates
- NCT04263285 · started 2026-10 · NA
Treatment of Depression Post-SCI